Clinical Trial Detail

NCT ID NCT03113500
Title Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

mature T-cell and NK-cell lymphoma

Therapies

Etoposide

Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone

Doxorubicin

Cyclophosphamide

Prednisone

Age Groups: senior adult

No variant requirements are available.